Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crotetamide SCHEMBL26013 | 1.00 | CYP3A4 (0.33) | CYP3A4LMNA | |
| Cropropamide SCHEMBL2967555 | 0.92 | CYP3A4 (0.30) | CYP3A4LMNA | |
| Cropropamide SCHEMBL25324 | 0.87 | — | — | |
| SCHEMBL18699228 | 0.74 | CYP3A4 (0.39) | CYP3A4LMNA | |
| SCHEMBL22053010 | 0.71 | CYP3A4 (0.40) | CYP3A4LMNA | |
| SCHEMBL25337345 | 0.69 | FDPS (0.34) | — | |
| SCHEMBL9500561 | 0.68 | TSHR (0.32) | — | |
| SCHEMBL16071866 | 0.66 | — | — | |
| SCHEMBL28719684 | 0.66 | — | — | |
| SCHEMBL12121535 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1017 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-03-15 | — | — | US | claimed |
| EP-1617816-B1 | NANOPARTICULATE MELOXICAN FORMULATIONS | ELAN PHARMA INT LTD (IE) | 2009-05-13 | — | — | EP | claimed |
| EP-1981502-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME | Harrogate Holdings (BM) | 2008-10-22 | — | — | EP | claimed |
| EP-1938803-A2 | Formulations comprising nanoparticulate meloxican | Elan Pharma International Limited (IE) | 2008-07-02 | — | — | EP | claimed |
| CN-100346832-C | Pharmaceutical dosage form for transmucosal delivery | PHARMACIA CORP (US) | 2007-11-07 | — | — | CN | claimed |
| WO-2007088489-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME | HARROGATE HOLDINGS (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070185145-A1 | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | HARROGATE HOLDINGS (BM) | 2007-08-09 | — | — | US | claimed |
| EP-1480624-B1 | PHARMACEUTICAL TABLET | PHARMACIA CORP (US) | 2006-11-29 | — | — | EP | claimed |
| EP-1471890-B1 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORP (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1608407-B1 | DISPERSIBLE FORMULATION OF AN ANTI-INFLAMMATORY AGENT | PHARMACIA CORP (US) | 2006-08-30 | — | — | EP | claimed |
| WO-2004082719-A1 | DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS | PHARMACIA CORPORATION (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040156872-A1 | Novel nimesulide compositions | ELAN PHARMA INTERNATIONAL LTD. | 2004-08-12 | — | — | US | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003066029-A2 | PHARMACEUTICAL DOSAGE FORM FOR MUCOSAL DELIVERY | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| WO-2003066030-A2 | PHARMACEUTICAL TABLET | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156872-A1 | Novel nimesulide compositions | NIM1K, NIT2, NCL | CYP3A4 1976/4885LMNA 3668/4885 |
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | CYP3A4 306/4885LMNA 2379/4885 |
| US-20120063996-A1 | NOVEL NIMESULIDE COMPOSITIONS | NIM1K, NIT2, NCL | CYP3A4 1976/4885LMNA 3668/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | CYP3A4 67/4885LMNA 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.